ArticleClinical and translational allergy2013
The placebo effect in allergen-specific immunotherapy trials.
Article in Clinical and translational allergy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- [Placebo effect in clinical trials with allergen-specific immunotherapy with inhalant allergens].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Pooled it
- Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.The Journal of allergy and clinical immunology · 2023Trial
- Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.Allergy · 2018Trial
- Article
- Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- [The effect of treatment expectations on pruritus and skin pain].Schmerz (Berlin, Germany) · 2022Review
- Dogmas, challenges, and promises in phase III allergen immunotherapy studies.The World Allergy Organization journal · 2021Review
- Shirazi thyme (Postepy dermatologii i alergologii · 2021Article
- First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients.The World Allergy Organization journal · 2021Article
- Precision medicine reaching out to the patients in allergology - a German-Japanese workshop report.Allergologie select · 2021Article
- Human sleep consolidates allergic responses conditioned to the environmental context of an allergen exposure.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Modulating local airway immune responses to treat allergic asthma: lessons from experimental models and human studies.Seminars in immunopathology · 2020Review
- Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs.Clinical and translational allergy · 2020Review
- Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials.Postepy dermatologii i alergologii · 2018Article
- Positive and negative AIT trials: What makes the difference?Allergo journal international · 2018Review
- Placebo effects in allergen immunotherapy: an experts' opinion.Allergo journal international · 2018Review
- Personalized Medicine in Allergic Asthma: At the Crossroads of Allergen Immunotherapy and "Biologicals".Frontiers in pediatrics · 2017Review
- Contextually Aided Recovery (CARe): a scientific theory for innate healing.Chiropractic & manual therapies · 2017Article
- T Cell Epitope Peptide Therapy for Allergic Diseases.Current allergy and asthma reports · 2016Review
- Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDouble-blind, placebo-controlled (DBPC) trials are the gold standard for demonstrating clinical efficacy and tolerability. The placebo effect, although an important feature in placebo-controlled studies, has never been systematically investigated in allergen-specific immunotherapy (SIT) studies. This study was performed to examine the placebo response in SIT trials that employed a baseline observational period and two treatment years using a symptom-medication-score (SMS) as the primary endpoint.
methodsThe placebo effect was evaluated in six DBPC SIT studies (five studies using subcutaneous SIT (SCIT) and one sublingual (SLIT)), two grass, two birch and two house dust mite (HDM) SIT, including a total of 472 adult patients treated with a placebo. The results were reported as changes from baseline of the SMS area under the curve after two years of perennial placebo therapy during the respective evaluation periods. Pollen counts and IgG4 levels were additionally analysed.
resultsSubcutaneously treated placebo patients displayed a marked decrease in the SMS. The mean placebo effect in the SCIT trials with comparable allergen exposure was up to 41% in the second treatment year and, in contrast, reached only 1% in the SLIT trial. Allergen exposure had an inverse influence on the placebo effect. No changes from baseline in allergen specific IgG4 antibodies were observed in the placebo-treated patients.
conclusionsSIT studies display a significant placebo effect, mainly observed in subcutaneous immunotherapy, with high variability depending on the route of application and allergen exposure. Our findings indicate the differential role of the placebo effect in SIT efficacy depending on the route of administration and pollen exposure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.